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Abstract
Background: Hyperosmotic glucose is injected intravenously when an intravenous
glucose tolerance test (IVGTT) is initiated. The extent and time period of plasma
volume expansion that occurs in response to the glucose load has not been studied
in the perioperative setting.
Methods: Twenty-two non-diabetic patients aged between 57 and 76 years (mean
68) underwent an IVGTT, during which 0.3 g/kg of glucose 30% (1 ml/kg) was
injected as a bolus over one minute, one day before and two days after hip
replacement surgery. Twelve blood samples were collected over 75 minutes from
each patient. The turnover of both the exogenous glucose and the injected fluid
volume was calculated by means of mass balance and volume kinetic analysis.
Results: The IVGTT raised plasma glucose by 9 mmol/L and the plasma volume by
8%. The extracellular fluid volume increased by 320 (SD 60) ml of which 2/3 could be
accounted for in the plasma. The half-life of the exogenous glucose averaged
30 minutes before surgery and 36 minutes postoperatively (P < 0.02). The glucose
elimination governed 86% of the decay of the plasma volume expansion, which
occurred with a half-life of 12 minutes before to 21 minutes after the surgery
(median, P <0.001).
Conclusion: Hyperosmotic glucose translocated intracellular water to the plasma
volume rather than to the entire extracellular fluid volume. The preferential re-
distribution acts to dilute the plasma concentrations used to quantify insulin
sensitivity and ß-cell function from an IVGTT. The greater-than-expected plasma
dilution lasted longer after than before surgery.
Keywords: Kinetic model, Intravenous glucose tolerance test, Plasma volume
expansion
Background
The intravenous glucose tolerance test (IVGTT) is a tool for the assessment of in-
sulin sensitivity and ß-cell function in diabetes research [1,2] and perioperative
studies [3,4]. A bolus injection of glucose i sg i v e na n dt h ep l a s m ac o n c e n t r a t i o n s
of glucose and insulin are usually measured over three hours. The data can be an-
alyzed by, for example, the minimal model [5] and the single delay model [6]. The
IVGTT requires frequent blood sampling and is labor-intensive. Therefore, the
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the perioperative setting [3].
Another problem is that the IVGTT is likely to cause a sudden increase of the
plasma volume. Although the injected fluid volume is small (60–80 ml), the glu-
cose solution has traditionally six times the osmotic strength of body fluids. The
hypertonicity translocates water from the intracellular (ICF) to the extracellular
fluid (ECF) space, where it augments the plasma volume expansion [7]. The magni-
tude of the plasma volume expansion resulting from an IVGTT over time has pre-
viously been studied in young, healthy volunteers [8], although the test is usually
performed in elderly patients. Moreover, plasma volume kinetics has not been stud-
ied in the perioperative setting.
In the present study, the volume kinetic models developed for hypertonic fluids
[7,9] and glucose [10,11] were combined to analyze the disposition of the injected
test solution during IVGTT in 22 patients before and after hip replacement sur-
gery. The reason why two models have to be combined is that the hypertonic glu-
cose is a driving force for body-fluid shifts. Hip replacement is performed in senior
citizens and the comparison of pre- and postoperative data illustrates the effect of
surgical stress on glucose turnover and its subsequent influence on the plasma
volume.
Patients and methods
Patients
Twenty-two non-diabetic patients, 15 females and seven males, aged between 57 and
76 years (mean 68), and with a body weight of 46–101 kg (mean 80), were studied before
and after undergoing elective total hip replacement surgery at the Orthopedic Departments
at Södersjukhuset, Stockholm and Södertälje Hospital, Södertälje. The study was approved
by the Regional Ethics Committee of Stockholm (Ref. 2011/1141-31/3). Each patient gave
written consent for participation.
Intravenous glucose tolerance test
An IVGTT was performed to estimate the insulin sensitivity of each participant.
The patients arrived at the laboratory at 8 AM on the day before their surgery and
two days after their surgery. On both occasions, the patients had fasted since mid-
night. An intravenous catheter was inserted into an antecubital vein of one arm,
for infusion of insulin and glucose, respectively. Another cannula used for blood
sampling was inserted into an antecubital vein of the opposite arm.
After a 30-minute equilibration period to obtain hemodynamic steady state, a
short regular IVGTT was performed by administrating 0.3 g/kg of glucose in a
30% solution over one minute. Blood was sampled from the contralateral
antecubital vein at the 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60 and 75-minute intervals
for measurement of the plasma glucose and blood hemoglobin (Hb) concentrations.
Plasma glucose was measured by the glucose oxidase method (Modular P, Roche
Diagnostics, Tokyo, Japan) and Hb by colorimetry (Technicon Advia, Bayer,
Tarrytown, NY, USA), at the certified clinical chemistry laboratory at the
Karolinska University Hospital.
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Glucose
Plasma concentration G at time t when glucose was infused at rate Ro was calculated
using the following differential equation:
dG −Gb ðÞ
dt
¼
Ro
Vd
−
CL
Vd
Gt ðÞ −Gb ðÞ
where Gb is the baseline glucose, Vd is the volume of distribution, and CL is the clear-
ance. Removal of glucose from Vd corresponds, in the absence of glucosuria, to the up-
take of glucose by cells [10,11]. As very high concentrations of glucose (“overshoot”)
could sometimes be detected just after the injection, all kinetic analyses disregarded the
data points between two and eight minutes.
Fluid
Hypertonic glucose translocates water from the intracellular (40% of body weight
[BW]) to the extracellular (20% of BW) fluid space in proportion to the added amount
of osmotic active molecules and the accompanying water volume. The translocated vol-
ume ft, resulting from the injection, was obtained by the following mass balance calcu-
lation which was based on the induced deviation from the baseline osmolality in all
body fluids, which is 295 mosmol/kg [7]:
BW⋅20%⋅295 þ infused osmoles
BW⋅20% þ ft þ infused volume
¼
BW⋅40%⋅295
BW⋅40%−ft
The calculated value of ft is then inserted into a one-volume kinetic model [10],
which calculated the baseline volume of distribution (V) and the clearance (CL) for the
sum of the injected (Ro) and translocated (ft) fluid volumes. In this kinetic model, fluid
added to the kinetic system expands V to v, which strives to return to V by the elimin-
ation of fluid at a rate proportional to a constant CL of the dilution of V, and second, a
baseline loss (CLo) fixed to 0.4 ml/min to account for evaporation and basal diuresis.
The volume change of v is then expressed as [12]:
dv
dt
¼ Ro þ ft−CLo−CL
v−V ðÞ
V
The dilution of v is given by (v-V)/V and was equal to the plasma dilution as derived
from the blood Hb concentration at baseline (time 0) and at a later time t. Hence:
[(Hbo/Hb(t))–1]/(1–hematocrito). While V is a functional body fluid space, tracer
methods support that the Hb-derived plasma dilution can be used to accurately infer
the percentage expansion of the plasma volume [13-15].
The optimal estimates for the unknown parameters in the glucose (Vd and CL) and
fluid models (V and CL) were calculated for each of the 22 experiments individually
through nonlinear least-squares regression based on a modified Gauss-Newton method.
The input variables were plasma glucose, plasma dilution, and t. No weights were used.
The software was Matlab 4.2 (Math Works Inc., Natick, MA, USA).
The half-life (T1/2) of the glucose load was given by [ln 2 Vd / CL] while T1/2 of the
induced plasma volume expansion was taken as [ln 2V / CL].
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The results were presented as mean, standard deviation (SD) and, when there was
skewed distribution, as the median (25
th-75
th percentile range). Between-patient vari-
ability of plasma glucose and plasma dilution was calculated as the absolute residual
error between each individual measurement and time-matched modeled data based on
the median optimal parameter estimates for the group, as shown in the Table 1. Differ-
ences between pre- and postoperative data were compared by the Wilcoxon’s matched-
pair test, using SPSS version 20 (IBM 2011). P<0.05 was considered statistically
significant.
Results
The amount of injected glucose solution was 80 (SD 14) ml. Several patients reported
transient (1–2 min) warmth from the injection site in the arm to the face and legs, and
occasionally an unpleasant feeling in the palate region.
The baseline plasma glucose concentration was 7% higher and Hb was 19% lower
after surgery than before (Table, top). On both occasions, the modeled rise in plasma
glucose was 9 mmol/L (Figure 1). The surgery increased T1/2 of the glucose by 20%,
which was due to a reduction of CL while Vd remained essentially constant (Table, mid-
dle). Surgery also reduced between-patient variability of plasma glucose by 18% (P <
0.012).
The injection of a 30% glucose solution translocated water from the ICF space, which
was calculated by mass balance to be 1.82 ml for each mmol of injected glucose (=ft).
As the dose was 0.3 g/kg, the amount of translocated fluid could be estimated to be
241 (45) ml. Thus, the sum of the injected and translocated fluid volumes would theor-
etically amount to 320 (60) ml.
Most of this volume could be found in the intravascular compartment. The measured
maximum dilution of venous plasma amounted to 8% (Figure 2) and the volume kinetic
Table 1 Baseline and kinetic data for injected glucose and fluid during an intravenous
glucose tolerance test before and after hip replacement surgery in 22 patients
Before surgery After surgery Statistics
Plasma glucose, baseline (mmol/L) 5.6 (5.3-5.8) 6.0 (5.8-6.5) P<0.001
B-Hb concentration (g/dL) 12.4 (12.0-13.3) 10.0 (9.0-10.6) P<0.001
Glucose kinetics
Vd (L) 12.7 (10.2-15.6) 14.0 (12.1-14.8) NS
CL (ml/min) 325 (272–385) 260 (220–306) P<0.02
T1/2 (min) 30 (19–34) 36 (30–45) P<0.02
Fluid kinetics, no glucose uptake
V (L) 2.94 (2.17-3.60) 2.83 (2.62-3.22) NS
CL (ml/min) 200 (70–261) 93 (64–189) P< 0 001
T1/2 (min) 12 (5–30) 21 (10–33) P<0.001
Fluid kinetics, with glucose uptake
V (L) 2.79 (2.50-3.42) 2.73 (2.40-3.05) NS
CL (ml/min) 37 (−7 to 165) 9 (−14 to 55) P<0.02
Data is the median and 25
th-75
th percentile limits.
The Wilcoxon matched-pair test was used for statistics. NS =not statistically significant.
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ference depending on whether the kinetic analysis was based on data obtained before
or after surgery (Table). The maximum plasma volume expansion, which equals prod-
uct of plasma dilution and V, would then average 230 ml. Hence, two-thirds of the sum
of injected and translocated ICF volume could be accounted for in the plasma.
The rate of decay of the plasma volume expansion occurred more slowly after surgery
than before (Figure 2). The surgery also decreased the between-patient variability of the
plasma dilution by 32% (P<0.001). The fluid CL was only half as high, which almost
doubled T1/2 for the volume expansion, from 12 minutes to 21 minutes (Table,
bottom).
The fluid CL became reduced by 85% (median) if account was taken of the water vol-
ume that was osmotically re-translocated to the cells along with the uptake of glucose
was disregarded (Table, bottom). Some CL values even became negative, which made
the authors refrain from calculating T1/2.
Discussion
The clinician should be aware that injecting hypertonic glucose during an IVGTT in-
duces an abrupt expansion of the plasma volume in all patients. Fortunately, the magni-
tude in elderly surgical patients is not greater than in younger healthy volunteers [8],
but the hemodynamic consequences are naturally dependent on the cardiac reserves of
Figure 1 The increase in plasma glucose induced by an intravenous glucose tolerance test (IVGTT),
consisting of an intravenous injection of 0.3 g/kg of glucose over 1 minute, performed before and
after hip replacement surgery. Each experiment is represented by a thin line and the modeled average
by a thick line.
Figure 2 The dilution of venous plasma in response to an IVGTT performed before and after hip
replacement surgery. Each experiment is represented by a thin line and the modeled average by a
thick line.
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pensation in patients with worsening heart failure. We recommend that clinicians be
prepared to administer a vasodilator drug intravenously if performing an IVGTT in
such patients.
The volume kinetic calculations showed that the hypertonic glucose increased the
plasma volume by 230 ml within 2 minutes. This volume was obtained by multiplying
the maximum Hb-derived plasma dilution with the size of V. The latter is a functional
body fluid space but can be regarded to equal the plasma volume when the size is
slightly smaller than an estimate based on anthropometric measures: the blood volume
in these patients can be assumed to equal 7% of the body weight and the baseline
plasma volume, with regard to the hematocrit, would then be 3.6 L. Using the theoret-
ical 3.6 L as the basis for the calculation the maximum plasma volume expansion
would be 288 ml. The difference from 230 ml might be due to the old age of the stud-
ied patients, but could also be within the range of errors inherent in the methods used
and the assumptions made in anthropometric estimates. The total expansion of the
ECF volume based on mass balance was estimated to be only slightly larger, 320 ml.
These calculations illustrate that the intravascular volume expansion was dispropor-
tionately large based on the belief that osmosis-driven translocation of water from the
ICF distributes equally throughout the ECF space. As seen in several previous studies,
the size of body fluid space expanded by fluid (V) is remarkably low when being a part
of glucose administration. In fact, V is more consistent with the plasma volume (here,
2.7-2.9 L) than with the size of the ECF space [8,10,16]. This is surprising, as the vol-
ume of distribution for the exogenous glucose (Vd) was four times larger. The differ-
ence between Vd and V might reflect higher compliance for glucose molecules than for
water in penetrating and expanding the jelly matrix of the extravascular part of the
ECF space. However, this explanation is less likely as salt-containing isotonic and
hypertonic infusion fluids do expand extravascular parts of the ECF volume [7,9]. In
any event, to maintain osmotic equilibrium the difference between V and Vd assumes
that most of the injected glucose is exchanged for electrolyte-rich fluid at the border of
the capillary membrane.
How glucose affects fluid turnover is illustrated by the data on fluid elimination. After
the acute volume expansion, most of the excess fluid volume residing in the plasma
was eliminated by virtue of osmosis. Therefore, the T1/2 of glucose is apparently a key
factor for the duration of the plasma volume expansion following an IVGTT. Previous
studies of young healthy volunteers have yielded a T1/2 for glucose of between 11 mi-
nutes and 15 minutes [8,10], while during laparoscopic surgery in females at 40 years
of age T1/2 was 30 minutes [16]. The patients in the present study were almost 30 years
older and had a T1/2 of 30 minutes even before the surgical stress, which suggests that
plasma volume expansion after an IVGTT becomes more long-lasting due to both age
and surgery. The slower turnover of glucose after surgery is mainly caused by reduced
insulin sensitivity, which drops by approximately 35-50% after hip replacement [4]. Sur-
gery also reduced the between-patient variability of plasma glucose and Hb dilution,
which was probably due to alignment to similar degrees of the vascular tonus and de-
gree of “stress” postoperatively.
Glucose uptake did not account for the entire reduction of the plasma volume expan-
sion after the IVGTT was initiated. A residual reduction, which was apparently due to
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uptake on the decay of the volume expansion, and amounted to 15% of the total. This
is shown by the lower CL of fluid obtained when the calculations accounted for uptake
of glucose to the cells (Table, bottom). Renal excretion is the most likely mechanism
for such non-osmotic elimination, which is known to operate more slowly during the
postoperative phase, because of the influence of water-retaining “stress” hormones such
as cortisol and aldosterone [17]. However, as only a small fraction of the fluid was elim-
inated by non-osmotic mechanisms, the calculated elimination approached and even
passed zero elimination in some patients. This shows that the accuracy of the methods
and the assumptions made were not always capable of capturing fluid shifts amounting
to 20–30 ml. On the other hand, all residual eliminations would have been positive if
the baseline fluid loss of 30 ml (CLo) had not been deducted from plasma volume
expansion.
The clinical importance of the present calculations consists in the demonstration of
an abrupt increase of the plasma volume expansion that occurs when an IVGTT is ini-
tiated. The expansion is greater than would be expected based on belief that the water
translocated from the ICF by hypertonic glucose is evenly distributed throughout the
ECF volume. The small Vd for the injected and translocated fluid volumes means that
hypertonic glucose is approximately three times more effective than hypertonic saline
to expand the plasma volume [7,9,18]. The volume expansion obtained from 30% glu-
cose was also 10 times greater than for Ringer’s acetate solution infused over 30 min in
the elderly [17]. The volume expansion will also last much longer if the subject is in a
state of insulin resistance, such as during the postoperative period in senior citizens.
A scientific concern raised by the present study is that the plasma dilution distorts
the relationship between amount and concentration of any substance measured in
plasma sampled during an IVGTT. The plasma is likely to show more erroneously low
concentrations the earlier the IVGTT experiment sampling is made. For example,
plasma insulin sampled early during an IVGTT will show a 8% lower concentration
compared to insulin alone being injected. Twenty minutes later, when the plasma vol-
ume expansion is only 4%, the distortion will be only half as great. These effects act to
overestimate CL for glucose, while T1/2 becomes underestimated compared to calcula-
tions based on amounts. These considerations are probably trivial in most instances.
However, more complex kinetic calculations based on IVGTT, such as the minimal
model [5], single delay model [6] and deconvolution of C-peptide concentration [19],
are likely to be affected. These effects are not easy to predict or reconstruct with confi-
dence, since the variability of the plasma dilution response to IVGTT is greater than
the variability of the plasma glucose response (cf. Figures 1 and 2). However, for accur-
ate results with regard to amounts the input values in kinetic calculations should be
corrected by dividing all concentrations by the plasma dilution. The authors wish to
quantify these effects in subsequent works. Staggered by the strong plasma volume ex-
pansion reported here the authors also plan to compare the plasma volume expansion
resulting from hypertonic glucose with that obtained by small amounts of hypertonic
saline and other fluids.
Limitations of the present study include that the plots of plasma glucose over time
(Figure 1) show that an “overshoot” frequently occurred within the first minutes after
an IVGTT was initiated. The plasma glucose concentration was then transiently higher
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refrained from applying a two-compartment model as the “overshoot” was inconsistent
and the data points too few to allow detailed analysis. While this “overshoot” could
affect fluid distribution during the first minutes of the study, the curve-fitting routine
was set to disregard the plasma glucose concentrations measured between 2 and 8 min
of the experiments. These data were also omitted when the between-patient variability
in plasma glucose and Hb dilution was calculated.
Another limitation of this study was that diabetic patients were not included. As the
fluid clearance is governed almost completely by the rate of uptake of glucose in the
cells, patients with diabetes are likely to have even more long-lasting plasma volume
expansion than the postoperative patients studied here. A final limitation of the present
study was that no hemodynamic measurements were made, and these could have im-
proved the presentation.
Conclusion
The acute plasma volume expansion resulting from an IVGTT amounted to 8% both
before and after hip replacement surgery. The duration of the plasma volume expan-
sion was twice as long postoperatively than before the surgery. This effect was mostly
attributable to slower turnover of the injected glucose. For accurate results, calculations
based on an IVGTT should be corrected for plasma dilution induced by the hypertonic
glucose.
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